Objective-Pseudoxanthoma elasticum (PXE) is an autosomal recessive connective tissue disorder with involvement of the skin, the retina, and the cardiovascular system. Cardiovascular involvement is mainly characterized by mineralization and fragmentation of elastic fibers of blood vessels and premature atherosclerosis. We conducted an ultrasound study to investigate the cardiovascular phenotype and to propose recommendations for the management of patients with PXE and heterozygous ABCC6 mutation carriers. Approach and Results-Thirty-two patients, 23 carriers, and 28 healthy volunteers underwent cardiac and vascular ultrasound studies. Cardiac imaging revealed left ventricular diastolic dysfunction in patients with PXE with a significantly prolonged deceleration time and lower septal early diastolic velocities of the mitral annulus compared with controls. Carriers also demonstrated significantly prolonged deceleration time. Carotid-to-femoral pulse wave velocity was significantly increased in patients with PXE when compared with carriers and controls. Vascular imaging revealed a high prevalence of peripheral artery disease in both patients and carriers and a significantly higher carotid intima-media thickness compared with controls. Conclusions-The results of this study clearly demonstrate impaired left ventricular diastolic function, impairment of the elastic properties of the aorta, and a high prevalence of peripheral artery disease in patients with PXE. Carriers also seem to exhibit a cardiovascular phenotype with mainly mild diastolic dysfunction and accelerated atherosclerosis. Increased awareness for cardiovascular events in both patients and heterozygous carriers is warranted. 
P seudoxanthoma elasticum (PXE, OMIM# 264800) is a rare autosomal recessive disorder caused by mutations in the ABCC6 gene and characterized by ectopic mineralization and fragmentation of elastic fibers. The estimated prevalence of PXE is 1 in 50 000, with a carrier frequency of 1 to 2 per 300. 1 The clinical manifestations primarily occur in 3 organ systems: the skin, the eyes, and the cardiovascular system. The cutaneous manifestations ( Figure I in the online-only Data Supplement) are usually the first to appear and include peau d'orange, yellowish papules, and inelastic skinfolds, which primarily affect the flexural areas of the body. The characteristic ophthalmologic findings in patients with PXE ( Figure I in the online-only Data Supplement) are the presence of angioid streaks, subretinal neovascularization and hemorrhage, and pattern dystrophy of the macula and chorioretinal atrophy leading to severe impairment of visual acuity. 2 Cardiovascular complications are mainly caused by accelerated atherosclerosis. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Carriers of 1 ABCC6 mutation (further referred as carriers) can present with a phenotype, albeit milder and usually limited to the cardiovascular system. They do not tend to develop skin or ocular manifestations as in patients with PXE although anecdotal reports have suggested that carriers may occasionally have severe ocular manifestations. 13 Also, histological dermal alterations tend to be less severe than those seen in patients with PXE. 14 PXE is clinically characterized by significant inter-and intrafamilial heterogeneity in the extent and severity of the phenotype. 15 With >300 different mutations reported to date, comprehensive genotype-phenotype analysis failed to reveal a significant correlation between the type of ABCC6 mutation identified and the predicted effect on the expression of the protein, the age of onset, and severity of the disease. 16 It is thought that the clinical heterogeneity results from the influence of modifier genes and environmental factors.
Unfortunately, to date few modifier genes with clinical use have been identified. 18 The ABCC6 gene (chrom. 16p13.1) codes for an ATPdependent transmembrane transporter, which is most abundant in the liver and kidney. Remarkably, the expression of the ABCC6 transporter in tissues clinically affected by PXE is very low. 19 This observation led to the hypothesis that PXE is primarily a metabolic disorder in which circulating serum factor(s) plays a role. 17 Another, and probably complimentary, pathogenetic mechanism is the so-called cellular hypothesis in which fibroblast perturbation may evoke local mineralization and elastic fiber alterations. This hypothesis is based on the observation that elastic fiber alterations are not present homogeneously throughout the skin and blood vessels of patients with PXE, but only in peculiar regions. Moreover, PXE skin fibroblasts exhibit a distinct behavior with altered biosynthetic expression profile and cell-cell and cell-matrix interactions compared with fibroblasts from normal subjects. [20] [21] [22] This study focuses on the cardiovascular phenotype of patients with PXE and carriers. Cardiovascular changes in patients with PXE are characterized by (1) mineralization and fragmentation of elastic fibers of the internal elastic lamina, medial and adventitial layers of medium-sized arteries and aorta, as well as of the endocardium, pericardium, connective tissue around vessels in the myocardium and vascular structures of the heart such as intramyocardial arterioles and epicardial coronary arteries 9, [22] [23] [24] [25] ; (2) high prevalence of atherosclerotic plaques 3, 26 ; and (3) accumulation of proteoglycans in the arterial media. 9 As a result of these changes, vascular complications such as peripheral artery disease (PAD), coronary artery disease (CAD), stroke (predominantly resulting from ischemic cerebral small vessel disease), and gastrointestinal hemorrhage can occur. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 23, 27 Also, cardiac involvement with left ventricular (LV) diastolic dysfunction has been reported. 28 Importantly, carriers also demonstrate cardiovascular involvement with increased risk of premature CAD, PAD, and anecdotal incidence of ischemic stroke. 3, [6] [7] [8] 12 Whether ultrastructural changes of cardiovascular tissue with elastic fiber mineralization and fragmentation and proteoglycan accumulation, as seen in patients, are also present in carriers is not known. Moreover, no studies are available on LV function in carriers.
The purpose of this study was to investigate the cardiovascular phenotype of both patients with PXE and carriers by assessing LV function, elastic properties of the aorta, and carotid arteries and by evaluating the prevalence of atherosclerotic plaques and stenosis in neck and lower limb arteries. In a next step, we aimed to provide a guideline for cardiovascular diagnostics, preventive treatment strategies, and follow-up of patients and carriers.
Materials and Methods
Materials and methods are available in the online-only Supplement.
Results

Baseline Characteristics of the Study Population
There were no significant differences in height, weight, and body mass index between groups ( 
Cardiac Data
Echocardiographic data of systolic and diastolic parameters are presented in Table 3 . Significant valvular heart disease was excluded in all subjects. Mitral valve prolapse was seen in 1 patient; this was not associated with significant regurgitation. LV 
Vascular Data
Vascular data are presented in Table 4 . Linear regression analysis was applied with pulse wave velocity (PWV) as dependent variable and PXE status and age as independent variables. Patients with PXE had a significantly higher PWV compared with controls (B=1. 8 Lower extremity artery disease was present in 42.3% and 38.5% of patients and carriers, respectively. Atherosclerosis of the neck arteries was found in 32.3% and 4.8% of patients and carriers, respectively. The mean age at which atherosclerotic plaques in lower limb and neck arteries were detected was 55.6 years (13.2; range, 37-80 years) for patients and 58.4 years (8.2; range, 47-66 years) for carriers.
Discussion
The results of this study clearly demonstrate impaired LV diastolic function, impairment of the elastic properties of the aorta, and a high prevalence of PAD in patients with PXE. Hypertension is defined as SBP >140 mm Hg and DBP >90 mm Hg during repeated measurements or use of antihypertensive medication. 29 Hypercholesterolemia is defined as LDL-C ≥4.2 mmol/L (160 mg/dL), total cholesterol ≥6.2 mmol/L (240 mg/dL), and the use of a cholesterol lowering agent. 30 BMI indicates body mass index; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein-cholesterol; and SBP, systolic blood pressure.
*P value <0.05 means a significant difference in number between the patient vs control group (fourth column) and carrier vs control group (last column). NP CAD indicates coronary artery disease; LEAD, lower extremity artery disease; NP, not prevalent; PAD, peripheral artery disease; and RP, reported prevalence in the literature. CAD is defined as a history of stable angina, acute coronary syndrome, or coronary artery bypass graft surgery/percutaneous transluminal coronary angioplasty. The presence of PAD is defined as the presence of atherosclerotic plaques or stenosis of lower limb arteries (common, superficial, or deep femoral artery), indicated by LEAD, or of the carotid arteries (common carotid artery, internal or external carotid artery) determined by duplex echo recordings. Hypertension is defined as systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg during repeated measurements or use of antihypertensive medication. 29 *P value <0.05 means a significant difference in number between the patient vs carrier group.
Also, carriers seem to exhibit a cardiovascular phenotype with mainly (mild) diastolic dysfunction and indications for accelerated atherosclerosis.
Diastolic Dysfunction
We observed mild but significant alterations in diastolic function parameters in patients with PXE and heterozygous ABCC6 mutation carriers compared with healthy volunteers. These findings cannot be explained by valvular dysfunction, structural LV abnormalities, or conventional cardiovascular risk factors. To the best of our knowledge only 1 previous study on LV function in patients with PXE is available, reporting similar findings with significantly lower E m and higher E/E m ratio; data on deceleration time were lacking. 28 Although the exact underlying pathophysiology of diastolic dysfunction in PXE is not well understood, some mechanisms have been proposed, including (1) intrinsic histological alterations [22] [23] [24] and (2) myocardial ischemia caused by premature CAD and altered myocardial microcirculation. [5] [6] [7] [8] 12 The first hypothesis postulates that elastic fiber alterations of myocardial tissue of PXE subjects could cause changes in passive elastic properties of the myocardium with impairment of LV relaxation. The second hypothesis states that the presence of CAD with (silent) myocardial ischemia can cause impairment in myocyte relaxation and hence in diastolic function without obvious impairment of LV ejection fraction. 28, 32, 33 Furthermore, the myocardial microcirculation in patients with PXE also shows features reminiscent of PXE including mineralization and fragmentation of the elastic fibers, which might also compromise the myocardial oxygen supply. 25 Nevertheless, none of the PXE subjects enrolled in this study had clinical evidence of myocardial ischemia. Clinical workup with exercise stress test, myocardial perfusion imaging, and coronary artery CT might be possible approaches to investigate this hypothesis.
34,35
Vascular Data
Our vascular studies revealed abnormal elastic properties of the aorta with higher carotid-to-femoral PWV in patients with PXE compared with controls. In carriers, we found no significant difference in PWV when compared with controls. However, a tendency toward accelerated age-dependent stiffening was present in both patients and carriers (Figure 1 ). It is conceivable that elastic fiber mineralization and fragmentation in PXE arteries lead to an increase in arterial stiffness. 36 In addition, the presence of atherosclerotic plaques, which occur more frequently in PXE, is known to enhance stiffening of the arterial system. 37 Accordingly, we found a higher PWV in patients with PXE and carriers with PAD although this observation was not significant.
In accordance with Boutouyrie et al 38 and Germain et al, 39 we observed no significant decrease in CDC between the different groups, but rather a tendency toward a slower decrease of CDC in function of age in patients (Figure 2 ). The latter has already been reported by Kornet et al. 9 In carriers we observed a similar trend. The findings on CDC could be explained by the accumulation of proteoglycans in the medial layer of arteries, as observed by Kornet et al. 9 There are indications that proteoglycans, because of their intrinsic material properties, lead to increased arterial wall elasticity thereby A indicates late transmitral flow velocities; DT, deceleration time; E, early transmitral flow velocities; E/A, ratio of early to late peak velocities; E m , septal early diastolic velocities of the mitral annulus; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; and LVESD, left ventricular end-systolic diameter.
P values *<0.05 and †<0.001 mean a significant difference in number between the patient vs control group (fourth column) and carrier vs control group (last column); and ‡values adjusted for covariates.
counteracting the effect of elastic fiber fragmentation and calcium deposition and thus possibly masking the expected reduced distensibility.
The apparent contradictory findings on the stiffer aorta, on the one hand, and the more elastic carotid artery, on the other hand, deserve further studies. A possible explanation could be found in the fact that elastic fiber alterations and proteoglycan accumulation are not homogeneously distributed along the arterial system in patients with PXE. 9, 22 The wall composition within 1 artery, but also between different arterial beds, may not be uniform. Depending on the artery studied, there might be differences in functional parameters. PWV measures stiffness over a broad arterial segment namely the aortic and aorto-iliac tract and might, therefore, be less influenced by the patchy pattern of intrinsic wall alterations in PXE. In contrast, CDC measures stiffness at 1 point of the carotid artery. Further research is definitely warranted on the relation between alterations in wall composition and their relation to functional properties between the different parts of the arterial tree in patients with PXE.
Carotid intima-media thickness was significantly increased in patients when compared with control subjects as also shown by Kornet et al 9 and Germain et al. 39 Various mechanisms have been suggested to explain carotid wall thickening and thus higher carotid intima-media thickness in PXE subjects, including accelerated atherosclerosis, proteoglycan accumulation, and stimulation of vascular smooth muscle cell proliferation by increased proteoglycan content and elastin abnormalities. 9, 39 To our knowledge, there are no histological reports on vascular smooth muscle cell proliferation in patients with PXE. Our report is the first to show abnormal carotid intima-media thickness in carriers.
Patients with PXE generally have a normal life span but are prone to vascular disease, such as CAD, PAD, and cerebrovascular disease. 3 Conversely, a large population-based study showed an association between premature CAD and a frequent mutation in the ABCC6 gene (R1141X). 12 As such, PXE can serve as a genetic model for the study of the pathophysiology of common cardiovascular diseases. We further reinforced our previous data and those reported by Lefthériotis et al 26 as we observed a considerably higher prevalence of atherosclerotic plaques in patients with PXE and carriers compared with the general population.
3,40 PAD was most prevalent from the fourth to fifth decade on, but most of the subjects were asymptomatic.
Implication of Cardiovascular Findings on Medical Management of Patients With PXE and Carriers
Although there is no causal treatment for PXE, early identification of patients and carriers is important in view of cardiovascular risk factor control for prevention of cardiovascular comorbidity. Screening at initial diagnosis of both patients with PXE and carriers with blood pressure measurement, biochemistry with analysis of the lipidogram, echocardiography, assessment of the ankle-brachial index and duplex ultrasound of the neck arteries, and the lower extremity arteries is advised. When blood pressure is increased at screening, further diagnostic work-up with 24-hour blood pressure monitoring and exercise stress test to evaluate the presence of exercise-induced hypertension is recommended.
PAD rarely leads to hemodynamically important vessel obstruction in patients with PXE or carriers. 3, 26 The rate of follow-up for PAD should, therefore, depend on findings at initial examination. In asymptomatic patients and carriers, follow-up with ultrasound and ankle-brachial determination every 3 to 5 years seems a plausible rate. Secondary prevention strategies may be initiated according to ultrasound findings. 41 However, antiplatelet agents, advised in secondary prevention of PAD, are not routinely recommended in patients with PXE because of the increased risk of gastrointestinal bleeding.
3,27
Figure 1. Scatter plot presenting the evolution of pulse wave velocity (PWV; m/s) in function of age (years) in patients, heterozygous ABCC6 mutation carriers, and control subjects. The slope of the regression line is steeper in patients (pat, dotted line) and carriers (car, discontinuous line) compared with controls (co, full line), suggesting a faster increase in aortic stiffness with aging in both patients and carriers compared with controls. Figure 2 . Scatter plot presenting the evolution of the carotid distensibility coefficient (CDC; 10 −3 /mm Hg) in function of age (years) in patients, heterozygous ABCC6 mutation carriers, and control subjects. Patients (pat, dotted line) and carriers (car, discontinuous line) have a tendency toward a slower decrease of CDC with aging compared with controls (co, full line) as reflected by a slower decline of the regression slope in patients and heterozygous carriers.
LV diastolic, but not systolic, function is altered in patients with PXE and carriers. The rate of echocardiographic followup depends on findings at initial examination. In general, cardiac imaging may be recommended every 3 to 5 years.
Further cardiac diagnostics for the detection of CAD can be performed primarily with exercise stress test and if indicated, catheterization.
Conclusions
In this study, we provide evidence for impaired myocardial relaxation, impairment of elastic properties of the aorta, and accelerated atherosclerosis in patients with PXE. Carriers also demonstrate cardiovascular involvement although to a milder extent. PXE can be considered as a systemic disorder influencing different pathophysiological pathways leading to the observed cardiovascular phenotype. PXE can serve as a genetic model as ABCC6 mutations and polymorphisms might enhance susceptibility for common cardiovascular diseases. Increased awareness of cardiovascular events in both patients and carriers is warranted.
Limitations
The small numbers inherent to the rarity of the disease are a major limitation. Echo recordings of neck and lower limb arteries of patients with PXE and carriers were reviewed retrospectively and in most cases only images of the common, superficial, and deep femoral artery were available and not of the entire lower limb arterial system. The presence of PAD is, therefore, possibly underestimated. Using CT of the lower limbs would have given a better overview of the extent of calcified atherosclerotic plaques.
